| Literature DB >> 33731685 |
Marc Cougnon1, Romain Carcy2, Nicolas Melis1,3, Isabelle Rubera1, Christophe Duranton1, Karine Dumas4, Jean-François Tanti4, Catherine Pons5, Nicolas Soubeiran5, Marina Shkreli5, Thierry Hauet6, Luc Pellerin6, Sébastien Giraud7, Nicolas Blondeau8, Michel Tauc9, Didier F Pisani1.
Abstract
Inhibition of the eukaryotic initiation factor 5A activation by the spermidine analogue GC7 has been shown to protect proximal cells and whole kidneys against an acute episode of ischaemia. The highlighted mechanism involves a metabolic switch from oxidative phosphorylation toward glycolysis allowing cells to be transiently independent of oxygen supply. Here we show that GC7 decreases protein expression of the renal GLUT1 glucose transporter leading to a decrease in transcellular glucose flux. At the same time, GC7 modifies the native energy source of the proximal cells from glutamine toward glucose use. Thus, GC7 acutely and reversibly reprogrammes function and metabolism of kidney cells to make glucose its single substrate, and thus allowing cells to be oxygen independent through anaerobic glycolysis. The physiological consequences are an increase in the renal excretion of glucose and lactate reflecting a decrease in glucose reabsorption and an increased glycolysis. Such a reversible reprogramming of glucose handling and oxygen dependence of kidney cells by GC7 represents a pharmacological opportunity in ischaemic as well as hyperglycaemia-associated pathologies from renal origin.Entities:
Year: 2021 PMID: 33731685 PMCID: PMC7969969 DOI: 10.1038/s41419-021-03577-z
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469